(R)-BAY1238097

Cat. No.:	HY-112316A		
CAS No.:	1564269-85-7		
Molecular Formula:	$C_{25}H_{33}N_5O_3$		
Molecular Weight:	451.56		
Target:	Epigenetic Reader Domain		
Pathway:	Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



Solvent & Solubility

In Vitro

DMSO : 150 mg/mL (332.18 mM; Need ultrasonic)
H_2O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2145 mL	11.0727 mL	22.1455 mL
	5 mM	0.4429 mL	2.2145 mL	4.4291 mL
	10 mM	0.2215 mL	1.1073 mL	2.2145 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: **10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline**
   Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution
2. Add each solvent one by one: **10% DMSO >> 90% corn oil**
   Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome[1][2].

IC_{50} & Target

BET[1].

REFERENCES

[1]. Lejeune, P., et al. (2015) Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 75(15 Suppl), 884.

[2]. Bernasconi E, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA